## KWCN-41

Cat. No.:	HY-149258		
CAS No.:	2913223-17	-1	
Molecular Formula:	C <sub>18</sub> H <sub>17</sub> N <sub>3</sub> O <sub>2</sub>		
Molecular Weight:	307.35		
Target:	RIP kinase;	Necropto	osis; Mixed Lineage Kinase
Pathway:	Apoptosis;	MAPK/ER	K Pathway
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

## SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
Pi	Preparing Stock Solutions	1 mM	3.2536 mL	16.2681 mL	32.5362 mL
		5 mM	0.6507 mL	3.2536 mL	6.5072 mL
		10 mM	0.3254 mL	1.6268 mL	3.2536 mL

BIOLOGICAL ACTIV	
Description	KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC <sub>50</sub> value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis. KWCN-41 also has anti-inflammatory effects <sup>[1]</sup> .
IC <sub>50</sub> & Target	RIPK1 88 nM (IC <sub>50</sub> )
In Vitro	<ul> <li>KWCN-41 (10, 50, 250 nM; 1 h) inhibits L929 cell necroptosis in a dosedependent manner and increases the number of cells in the viable cell zone<sup>[1]</sup>.</li> <li>KWCN-41 (10, 50, 250 nM; 0.5, 1.5, 2.5 h) inhibits the phosphorylation of RIPK1/3 and MLKL in L929 cells<sup>[1]</sup>.</li> <li>KWCN-41 (0-10 μM) inhibits TZ-induced necroptosis of L929 cells in a dose-dependent manner and similarly protects cells from TSZ (TNF-α, Smac mimetic, and z-VAD-FMK)-induced necroptosis of HT-29 and U937 cells<sup>[1]</sup>.</li> <li>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</li> <li>Cell Viability Assay<sup>[1]</sup></li> </ul>

ò

	Cell Line:	L929 cells
	Concentration:	10, 50, 250 nM
	Incubation Time:	1 h
	Result:	Inhibited L929 cell necroptosis in a Dosedependent manner and increased the number of cells in the viable cell zone.
n Vivo		$g/kg$ ; i.p.; 72 h) dose-dependently inhibits TNF- $\alpha$ -induced death and improves survival in mice <sup>[1]</sup> .
	Animal Model:	Inflammatory mouse model <sup>[1]</sup>
	· · ·	Inflammatory mouse model <sup>[1]</sup> 10, 25, 40 mg/kg
	Animal Model:	Inflammatory mouse model <sup>[1]</sup>

## REFERENCES

[1]. Cui N, et al. Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors. Eur J Med Chem. 2023 Mar 15;250:115190.

Caution: Product has not been fully validated for medical applications. For research use only.